From the management
Since its foundation in 1975, Kainos Laboratories, Inc. has been making every effort, as a company engaged in manufacturing and sales of in-vitro diagnostics, to develop and offer innovative products for the ultimate objective of contributing to the advancement of both preventive and clinical medicine.
Starting with the world’s first Serum Transaminase Measuring Reagent that utilizes the enzymatic method, Kainos has expanded its business scope with various products in the biochemistry, immunoserology and genetic testing fields. In recent years, its Carnitine Measuring Reagent and ADAMTS13 Activity Measuring Reagent were both included in the national insurance listing in Japan in 2018, both of which greatly contributed to the definitive diagnosis and formulation of treatment strategies by medical professionals.
Continuing our vigorous track record of R&D, Kainos launched a novel diagnostic marker for sepsis “Procalcitonin Measurement Reagent.” Because this reagent may be used on multipurpose automated analyzers commonly installed in various scales and types of hospitals, it is expected to help improve the operational efficiency in those hospitals, just as Kainos’ biochemical testing reagent “Multi-item Standard Serum” is already contributing to streamlining renal and hepatic functional tests. In the immunological testing field, Kainos is actively deploying its products for the blood transfusion testing market including the gel column-based testing equipment and related reagents with the special focus on the fully automatic blood testing system Erytra Eflexis that is well suited to the market in Japan.
Along with the constant evolution of the clinical diagnostics industry as a whole, customer requirements are growing more diversified than ever. Kainos commits itself to continue the R&D activities by capitalizing its proprietary technology as well as through collaboration with affiliated companies in order to differentiate and customize our products.
With its 50th anniversary approaching in 2025, Kainos continues to offer innovative products of the highest quality to healthcare professionals under its principle of customer centricity.
Starting with the world’s first Serum Transaminase Measuring Reagent that utilizes the enzymatic method, Kainos has expanded its business scope with various products in the biochemistry, immunoserology and genetic testing fields. In recent years, its Carnitine Measuring Reagent and ADAMTS13 Activity Measuring Reagent were both included in the national insurance listing in Japan in 2018, both of which greatly contributed to the definitive diagnosis and formulation of treatment strategies by medical professionals.
Continuing our vigorous track record of R&D, Kainos launched a novel diagnostic marker for sepsis “Procalcitonin Measurement Reagent.” Because this reagent may be used on multipurpose automated analyzers commonly installed in various scales and types of hospitals, it is expected to help improve the operational efficiency in those hospitals, just as Kainos’ biochemical testing reagent “Multi-item Standard Serum” is already contributing to streamlining renal and hepatic functional tests. In the immunological testing field, Kainos is actively deploying its products for the blood transfusion testing market including the gel column-based testing equipment and related reagents with the special focus on the fully automatic blood testing system Erytra Eflexis that is well suited to the market in Japan.
Along with the constant evolution of the clinical diagnostics industry as a whole, customer requirements are growing more diversified than ever. Kainos commits itself to continue the R&D activities by capitalizing its proprietary technology as well as through collaboration with affiliated companies in order to differentiate and customize our products.
With its 50th anniversary approaching in 2025, Kainos continues to offer innovative products of the highest quality to healthcare professionals under its principle of customer centricity.
